Author:
Kumar Vivek,Pathak Dharam Pal,Sandal Nidhi
Abstract
Abstract
Background
The active pharmaceutical ingredient (API) of USFDA-approved Radiogardase®-Cs capsule is ferric(III) hexacyanoferrate(II) which is commonly known as Prussian blue insoluble (PB). It enhances the elimination of radioactive or non-radioactive caesium/thallium (Cs(I)/Tl(I)) from the body. The API of Radiogardase®-Cs capsules is not available commercially; therefore, in-house API was synthesized and evaluated. The present study includes toxicity evaluation and in vivo Tl(I) removal efficacy of in-house synthesized and optimized PB prepared by direct (PB-1) and indirect (PB-2) synthesis methods. PB-1 and PB-2 were evaluated for acute and sub-acute oral toxicity in accordance with OECD guidelines in rats.
Results
No significant changes were observed in treatment groups as compared to the control group of acute and sub-acute oral toxicity studies. The food intake, water consumption, body weight, clinical signs, organ weight and histopathological, biochemical and haematological parameters were monitored. The study found no evidence of mortality. The results indicated that the synthesized PB-1 and PB-2 were safe. As a result, the study further examined PB-1 and PB-2 for removal of Tl(I) in rats. A significant increase in Tl(I) removal was observed when PB-1 and PB-2 were administered orally to rats in comparison to no treatment group. The Tl(I) removal efficacy of PB-1 and PB-2 was comparable to Radiogardase®-Cs treated group. Results showed reduction in the body burden of Tl(I) as well as a higher level of elimination of Tl(I) in faeces and urine.
Conclusions
The study provides substantial support regarding Tl(I) removal efficacy and safety of in-house synthesized PB-1 and PB-2 which can be used for formulation development.
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Aaseth J, Nurchi VM, Andersen O (2019) Medical therapy of patients contaminated with radioactive cesium or iodine. Biomolecules 9(12):856. https://doi.org/10.3390/biom9120856
2. Agency for Toxic Substances and Disease Registry (ATSDR) (1992) Toxicological profile for thallium. Atlanta (GA): U.S. Department of Health and Human Services, Public Health Service. Accessed 26 Jan 2023
3. Agrawal V, Sandal N, Singh AK, Pathak DP (2021) pH-dependent release matrix oral formulation of Prussian blue to improve its efficacy as an internal decorporation agent. Curr Drug Deliv 18(8):1162–1173. https://doi.org/10.2174/1567201818666210127093327
4. Al-Afifi NA, Alabsi AM, Bakri MM, Ramanathan A (2018) Acute and sub-acute oral toxicity of Dracaena cinnabari resin methanol extract in rats. BMC Complement Altern Med 18(1):50
5. Altagracia-Martinez M, Kravzov-Jinich J, Martinez JM, Camilo R, López-Naranjo F (2012) Prussian blue as an antidote against radioactives thallium and cesium poisoning. J Orphan Drugs Res Rev 2:13–21. https://doi.org/10.2147/ODRR.S31881
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献